Prognostic factors affecting ALS progression through disease tollgates
- PMID: 39680215
- DOI: 10.1007/s00415-024-12819-x
Prognostic factors affecting ALS progression through disease tollgates
Abstract
Background and objectives: Understanding factors affecting the timing of critical clinical events in ALS progression.
Methods: We captured ALS progression based on the timing of critical events (tollgates), by augmenting 6366 patients' data from the PRO-ACT database with tollgate-passed information using classification. Time trajectories of passing ALS tollgates after the first visit were derived using Kaplan-Meier analyses. The significant prognostic factors were found using log-rank tests. Decision-tree-based classifications identified significant ALS phenotypes characterized by the list of body segments involved at the first visit.
Results: Standard (e.g., gender and onset type) and tollgate-related (phenotype and initial tollgate level) prognostic factors affect the timing of ALS tollgates. For instance, by the third year after the first visit, 80-100% of bulbar-onset patients vs. 43-48% of limb-onset patients, and 65-73% of females vs. 42-49% of males lost the ability to talk and started using a feeding tube. Compared to the standard factors, tollgate-related factors had a stronger effect on ALS progression. The initial impairment level significantly impacted subsequent ALS progression in a segment while affected segment combinations further characterized progression speed. For instance, patients with normal speech (Tollgate Level 0) at the first visit had less than a 10% likelihood of losing speech within a year, while for patients with Tollgate Level 1 (affected speech), this likelihood varied between 23 and 53% based on additional segment (leg) involvement.
Conclusions: Tollgate- and phenotype-related factors have a strong effect on the timing of ALS tollgates. All factors should be jointly considered to better characterize patient groups with different progression aggressiveness.
Keywords: Amyotrophic lateral sclerosis tollgates; Disease progression; Kaplan–Meier analysis; Prognostic factors; Time trajectory projection.
© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflicts of interest: The authors report no competing interests. Ethics approval: This study was reviewed by the Mayo Clinic Institutional Review Board and deemed as an exempt study. Consent to participate: Not applicable. Consent for publication: Not applicable.
Similar articles
-
Mapping of critical events in disease progression through binary classification: Application to amyotrophic lateral sclerosis.J Biomed Inform. 2021 Nov;123:103895. doi: 10.1016/j.jbi.2021.103895. Epub 2021 Aug 25. J Biomed Inform. 2021. PMID: 34450286
-
Tollgate-based progression pathways of ALS patients.J Neurol. 2019 Mar;266(3):755-765. doi: 10.1007/s00415-019-09199-y. Epub 2019 Jan 25. J Neurol. 2019. PMID: 30684209
-
[Analysis of disease progression rate and related factors in amyotrophic lateral sclerosis patients at initial visit].Zhonghua Yi Xue Za Zhi. 2022 Jan 18;102(3):222-227. doi: 10.3760/cma.j.cn112137-20210728-01681. Zhonghua Yi Xue Za Zhi. 2022. PMID: 35042292 Chinese.
-
Amyotrophic Lateral Sclerosis Regional Variants (Brachial Amyotrophic Diplegia, Leg Amyotrophic Diplegia, and Isolated Bulbar Amyotrophic Lateral Sclerosis).Neurol Clin. 2015 Nov;33(4):775-85. doi: 10.1016/j.ncl.2015.07.003. Epub 2015 Sep 8. Neurol Clin. 2015. PMID: 26515621 Free PMC article. Review.
-
Cognitive and behavioural impairment in amyotrophic lateral sclerosis: A landmark of the disease? A mini review of longitudinal studies.Neurosci Lett. 2021 May 29;754:135898. doi: 10.1016/j.neulet.2021.135898. Epub 2021 Apr 15. Neurosci Lett. 2021. PMID: 33862143 Review.
References
-
- Morris J (2015) Amyotrophic lateral sclerosis (ALS) and related motor neuron diseases: an overview. Neurodiagn J 55(3):180–194 - PubMed
-
- Kiernan MC, Vucic S, Cheah BC et al (2011) Amyotrophic lateral sclerosis. The Lancet 377(9769):942–955
-
- Thakore NJ, Lapin BR, Pioro EP, Pooled Resource Open-Access ALS Clinical Trials Consortium (2020) Stage-specific Riluzole effect in amyotrophic lateral sclerosis: a retrospective study. Amyotroph Lateral Scler Frontotemporal Degener 21(1–2):140–143
-
- Del Aguila MA, Longstreth WT, McGuire V, Koepsell TD, Van Belle G (2003) Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 60(5):813–819 - PubMed
-
- Abe K, Aoki M, Tsuji S et al (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7):505–512
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous